6 Key Highlights on Biobanking Equipment Market for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
48
6 Key Highlights on Biobanking Equipment Market for Forecast Period 2017-2022

Rockville, MD , July 17, 2018 (GLOBE NEWSWIRE) -- Fact.MR, in its new research, estimates an impressive growth for the global biobanking equipment market over the forecast period 2017 to 2022. Revenues from the global market for biobanking equipment are expected to exceed US$ 2,000 Mn by 2022-end.

A major trend observed in the market is conserving a newborn’s cord blood stem cells. The rise in demand for personalized medicine has been impacting the market growth over the past few years. This is mainly because of high unmet medical needs for development of effective therapies. Individuals around the world are banking their stem cells and tissues for future treatments, with increasing importance of requirement for annotated pathological & clinical data for developing personalized medicines. A number of research organizations are increasingly exploring methods to develop personalized treatments using biological samples. An example of this is signing of deals associated with biobanking, between Illumina, and the University of Colorado, Partners HealthCare, the Montreal Heart Institute, and the Vanderbilt University. These partnerships will collectively focus on improving healthcare and development of personalized medicines. These factors are expected to drive growth of the market during the forecast period.

Request For Sample Report - https://www.factmr.com/connectus/sample?flag=...rep_id=250

A major factor driving growth of the biobanking equipment market is growing demand for personalized medicine, which can be attributed to high unmet medical requirements for developing effective therapies. Personalized medicine implies treatments based on preferences, needs, and characteristics of patients. Individuals across the globe have been witnessed to bank their tissues and stem cells, in case any future treatment is required. Development of personalized medicine critically needs individual samples with annotated pathological and clinical data. Several research organizations are focusing on exploring ways for developments in personalized treatments with the help of biological samples.

The biobanking equipment market is highly fragmented on the back of the presence of numerous small as well as large vendors. As the biobanking equipment available in the market have similar nature, the market vendors are now shifting their focus towards differentiation of their services on the basis of automation of already existing technology, and the value-added services. This will further aid vendors in gaining a competitive edge in the global market. Some other factors influencing growth of the market include increasing requirement for discovery & development of cost-effective medicines, rising government as well as private funding for regenerative medicine research, soaring genomics research activities, and biobanking advancements across the globe.

Key Estimations on Future of Biobanking Equipment Market

1- Based on product type, equipment will continue to be dominant in the global market, with sales estimated to surpass revenues worth US$ 1,300 Mn by 2022-end. Between software & services and consumables, the former will exhibit a comparatively higher CAGR through 2022.

2- Biobanking equipment are expected to find the largest application in regenerative medicine. However, sales of biobanking equipment for clinical research-related application will register the fastest expansion through 2022.

To know the Latest Trends in Biobanking Equipment Market, Visit - https://www.factmr.com/report/250/biobanking-...ent-market

3- Although manual storage will remain preferred for biobanking equipment, sales of automated storage are poised to exhibit a higher CAGR in the market through 2022.

4- North America is anticipated to remain the largest market for biobanking equipment, with sales projected to expand at a CAGR of 7.6% through 2022. In addition, biobanking equipment market in Latin America and Japan will exhibit a parallel expansion through 2022.

5- Blood will remain sought-after among samples in the global biobanking equipment market. Sales of blood samples will hold the largest market revenue share, and register the fastest expansion through 2022. In contrast, tissues will register the lowest CAGR in sales through 2022.

6- Key players operating in the market include VWR Corporation, Thermo Fisher Scientific Inc., Qiagen N.V., Tecan Trading AG, Promega Corporation, Panasonic Healthcare Holdings, Merck KGaA, Hamilton Company, Greiner Holding AG, Chart Industries, Inc., Brooks Automation, Inc., and Becton, Dickinson and Company.

To Buy Biobanking Equipment Market Report, Check the link- https://www.factmr.com/checkout/250/S

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Mr. Rohit Bhisey Fact.MR 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Email: sales@factmr.com Web: https://www.factmr.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 76

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 110

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 43

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
Dental Exams Are Routine Until They Catch Something Early

Updated Category News Views 60

A mouth can look perfectly fine right up until it does not. That is the unglamorous value in the dental exam and X-rays visit described by Dr. Eric Runyon of Smiles Unlimited in Belton, Missouri: it is a structured look for trouble before pain, swelling, or a cracked tooth forces the issue. Nobody throws a parade for preventive care, but waiting for symptoms has a habit...

Continue Reading
Institutions Spread AI Bets as 2027 Risks Mount Higher

Updated Category News Views 89

Money managers are not fleeing the party; they are checking the fire exits. Natixis Investment Managers surveyed 515 institutions overseeing $42.7 trillion, and their 2027 posture is pretty plain: keep taking risk, just stop pretending every risk is the same. Inflation, rates, government debt, geopolitical fracture and an AI spending boom are all tugging at portfolios at...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
es

Top 5 Most Recently Viewed Articles

Fujitsu Enhances ETF Trading with New ASX Partnership

Updated Category News Views 212

Fujitsu Partners with ASX for ETF Trading Innovation Fujitsu Limited is teaming up with the Australian Securities Exchange (ASX) and the Tokyo Stock Exchange (TSE) to create a state-of-the-art SaaS-based Request for Quote (RFQ) platform. This exciting initiative represents a significant step forward in modernizing the ETF trading landscape. Understanding the New RFQ...

Continue Reading
Owens Corning Reports Strong Earnings and Future Outlook

Updated Category News Views 177

Owens Corning Shows Strong Performance in Recent Quarter Owens Corning (NYSE: OC) has exceeded expectations with its recent earnings results, garnering significant attention from investors. The company reported exceptionally strong numbers from its latest earnings announcement, which prompted a notable increase in its stock price. The performance indicates solid...

Continue Reading
Research Links Chorioamnionitis to Preterm Birth Developments

Updated Category News Views 182

Chorioamnionitis and Its Impact on Early Birth Recent research emphasizes the severe implications of moderate to severe chorioamnionitis (HCA) associated with preterm births. Experts from Cincinnati Children's Hospital have confirmed that these infections not only trigger preterm deliveries but also lead to significant neurodevelopmental issues in early childhood. Study...

Continue Reading
Micron Shifts Focus: Exiting Consumer Market for AI Future

Updated Category News Views 305

Micron Technology's Significant Move Micron Technology, Inc. (NASDAQ: MU) has announced a strategic decision to exit its Crucial consumer business, ceasing the sale of Crucial-branded products through various global retailers and distributors. This transition marks a significant pivot aimed at refocusing efforts toward emerging market opportunities, especially in...

Continue Reading
China's COMAC Strives for Growth in Vietnam's Aviation Sector

Updated Category News Views 449

China's Ambitious Move into Vietnam's Aviation Market China's state-owned aircraft manufacturer, COMAC, is making significant strides to penetrate the international aviation market. The focus is currently on gaining approval for its C909 jets in Vietnam, a move indicative of a broader strategy to enhance its global presence. This initiative highlights the ongoing...

Continue Reading